Multi-Target HDAC Inhibitor CUDC-101 Enhances PSMA Expression and Improves Radioligand Therapy in PSMA-Low Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #OP-484; Pres time: Oct 19, 2026; 04:45 PM - 06:15 PM; Location: Hall E2; "CUDC-101 increased PSMA expression and radioligand uptake, improving the therapeutic efficacy of 177Lu-PSMA-617 in vitro and in vivo. This multi-target HDAC inhibitor strategy overcomes PSMA heterogeneity and enhances tumor targeting. These findings suggest a therapeutic approach to expand RLT applicability, offering a new option for patients with PSMA-low prostate cancer."
Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • EGFR • FOLH1 • HER-2
|
|
H. Jung 1, 2, 3; K. Kang 1, 2, 3; H. Youn 1, 3, 4
|